Despite multimodal therapy, patients suffering from glioblastoma (GBM) still have a dismal prognosis. The identification of cancer stem cells (CSC) in brain tumour tissue, yielded hope that the vulnerable target to combat GBM has been found. Several study groups worldwide concentrate nowadays on therapeutic strategies that effectively target CSC. Since in our laboratory has been revealed that taurolidine, a derivate of the amino acid taurin, displays a potent antineoplastic effect in human glioma cell lines and in ex vivo malignant cell culture, this thesis focused on the susceptibility of glioblastoma CSC to taurolidine and temozolomide (TMZ), the most commonly used chemotherapeutic agent so far. Additionally, we investigated the most powerful derivative of taurolidine and tested its antineoplastic activity on CSC as well.